Earnings Ahead

MRK - Merck

97.44 0.9 0.93

Merck

Merck

About

Profile

Our corporate responsibility approach is aligned with our company’s focus on invention, and underscores our commitment to overcoming the greatest obstacles to health and well-being, developing and rewarding our employees, protecting the environment, and


Headquarters

Kenilworth, New Jersey, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

MRK



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Merck trades higher as Keytruda, Gardasil drive Q1 growth amid COVID pill decline
  • Merck Non-GAAP EPS of $1.40 beats by $0.03, revenue of $14.48B beats by $660M
  • Democratic senators introduce bill to enhance CMS drug price negotiations
  • Pfizer, BioNTech hit new 52-week lows
  • Merck, AstraZeneca dip as FDA reviews cancer drug ahead of AdCom meeting
  • Will the Keytruda wave buoy Merck's Q1 results once again?
  • EU publishes proposed reforms for pharma industry
  • Bipartisan agreement reached in Senate prescription drug price legislation
  • What is behind biotech M&A resurgence?
  • Catalyst watch: Earnings blitz, Mobileye lockup expiration and the new one-day VIX debut
  • Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more
  • Prometheus soars 70%, Merck dips after ~$11B buyout deal
  • Prometheus Biosciences had other bidders besides Merck - report
  • Moderna, Merck post detailed Phase 2 data for mRNA cancer shot in melanoma
  • Merck inks ~$11B all-cash deal to acquire Prometheus
  • Merck said to be close to acquiring Prometheus Biosciences - WSJ
  • Ghana 1st in world to approve new malaria vaccine by Oxford
  • Hot Stocks: PGR drops on earnings; CNSL rises on buyout offer; MRK higher on analyst upgrade; EDIT gains; HOG slides
  • Merck upgraded at Citi despite Keytruda patent cliff
  • Merck's Keytruda combo gets FDA review for initial therapy in gastric, esophagus cancer

Earnings History

Date EPS / Forecast Revenue / Forecast
February 3, 2022 1.8 / 1.52 13.52B / 13.14B Beat!
October 28, 2021 1.75 / 1.55 13.15B / 12.32B Beat!
July 29, 2021 1.31 / 1.31 11.4B / 11.08B Beat!
April 29, 2021 1.33 / 1.53 12.08B / 12.61B
February 4, 2021 1.32 / 1.38 12.51B / 12.67B
October 27, 2020 1.74 / 1.44 12.55B / 12.21B Beat!
July 31, 2020 1.37 / 1.06 10.87B / 10.4B Beat!
April 28, 2020 1.5 / 1.34 12.06B / 11.48B Beat!
February 5, 2020 1.16 / 1.15 11.87B / 11.98B
October 29, 2019 1.51 / 1.24 12.4B / 11.64B Beat!
July 30, 2019 1.3 / 1.16 11.76B / 10.96B Beat!
April 30, 2019 1.22 / 1.05 10.82B / 10.47B Beat!
February 1, 2019 1.04 / 1.04 11B / 10.94B Beat!
October 25, 2018 1.19 / 1.14 10.79B / 10.89B
July 27, 2018 1.06 / 1.03 10.47B / 10.28B Beat!
May 1, 2018 1.05 / 1 10.04B / 10.09B
February 2, 2018 0.98 / 0.94 10.43B / 10,494M
October 27, 2017 1.11 / 1.03 10.33B / 10,545M
July 28, 2017 1.01 / 0.87 9.93B / 9,746M Beat!
May 2, 2017 0.88 / 0.83 9.43B / 9,250M Beat!
Date Price Open High Low Vol Change
Nov 20 97.44 96.98
98.8
96.66
9.1M 0.93%
Nov 19 96.54 96.78
97.55
95.26
13.1M -0.02%
Nov 18 96.56 96.56
97.29
95.42
14.1M 0.26%
Nov 15 96.31 97.92
97.92
94.48
16.5M -2.08%
Nov 14 98.36 99.18
99.4
97.95
8.7M -0.14%
 
Nov 13 98.5 98.51
99.45
97.9
8.9M -0.08%
Nov 12 98.58 100.76
100.77
98.5
12.3M -2.13%
Nov 11 100.73 102.53
103.4
100.46
10.1M -2.13%
Nov 8 102.92 101.48
103.23
101
9.2M 1.73%
Nov 7 101.17 101.44
101.69
100.85
8.7M 0.44%
Nov 6 100.73 103.18
103.23
100.6
9.6M -0.91%
Nov 5 101.65 101.36
101.73
100.52
6.7M -0.22%
Nov 4 101.87 102
102.53
100.94
9.2M -0.01%
Nov 1 101.88 101.78
102.72
101.21
10.2M -0.43%
Oct 31 102.32 100.93
103.23
98.6
17.4M -2.39%
Oct 30 104.83 103.46
105
102.9
13.9M 1.06%
Oct 29 103.73 104.32
105.11
103.7
9.3M -0.48%
Oct 28 104.23 104.6
105
103.93
7.0M 0.24%
Oct 25 103.98 106.49
106.49
103.86
9.6M -1.79%
Oct 24 105.88 106.05
106.62
105.26
8.3M -0.47%
Oct 23 106.38 106.74
107.36
106.2
8.3M -0.24%
Oct 22 106.64 105.91
106.9
105.71
11.6M 0.28%
Oct 21 106.34 109.08
109.17
106.18
11.4M -2.17%
Oct 18 108.7 109.9
109.92
108.56
9.5M -0.96%
Oct 17 109.75 110.14
110.19
109.5
8.5M -0.61%
Oct 16 110.42 111
111.2
109.02
8.7M -1%
Oct 15 111.53 109.96
111.58
109.89
9.1M 1.68%
Oct 14 109.69 109.43
110.07
108.68
8.1M -0.04%
Oct 11 109.73 109.1
109.92
107.9
8.6M 0.30%
Oct 10 109.4 110.7
110.83
109.17
6.0M -0.79%
Oct 9 110.27 108.41
110.3
108.2
8.6M 1.61%
Oct 8 108.52 107.97
108.75
107.81
8.8M -0.06%
Oct 7 108.59 109.69
110.98
108.18
8.7M -1.07%
Oct 4 109.77 109.49
110.3
109.39
9.7M -0.37%
Oct 3 110.18 111.82
112.08
109.82
10.3M -1.7%
Oct 2 112.08 114.55
114.6
111.98
9.0M -2.32%
Oct 1 114.74 113.96
114.79
113.11
7.7M 1.04%
Sep 30 113.56 113.61
114.01
112.7
10.9M -0.11%
Sep 27 113.69 113.17
114.34
113
11.9M 0.53%
Sep 26 113.09 113.88
114
112.93
11.1M -1.43%
Sep 25 114.73 115.3
116.02
114.62
7.9M -0.2%
Sep 24 114.96 115.85
116.26
114.32
9.8M -0.58%
Sep 23 115.63 117.2
118.16
115.52
6.7M -1.31%
Sep 20 117.17 117.27
117.5
116.41
21.2M -0.05%
Sep 19 117.23 118.9
119.2
116.29
10.0M -1.19%
Sep 18 118.64 118.2
119.38
117.87
11.1M 0.30%
Sep 17 118.29 118.97
119.14
117.73
7.9M 0.28%
Sep 16 117.96 115.8
118.37
115.8
7.8M 1.81%
Sep 13 115.86 116.09
116.77
115
6.7M 0.53%
Sep 12 115.25 114.47
115.5
114.04
8.3M 0.47%
Sep 11 114.71 114.94
115.89
114.27
7.8M -0.54%
Sep 10 115.33 115.21
116.09
113.33
12.7M -0.07%
Sep 9 115.41 113.15
116.9
112.41
14.9M -2.06%
Sep 6 117.84 119.1
120.3
117.65
8.6M -0.63%
Sep 5 118.59 116.61
120.07
116.35
12.0M 2.41%
Sep 4 115.8 116.66
116.73
114.47
7.7M -0.67%
Sep 3 116.58 118.26
118.84
116.42
7.6M -1.58%
Aug 30 118.45 117.27
118.75
117.15
8.9M 0.84%
Aug 29 117.46 117.93
118.39
116.79
7.2M 0.05%
Aug 28 117.4 116.6
118.02
116.24
5.4M 0%